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A B S T R A C T
The aim of this prospective study was to analyse the quality of life in patients with blepharospasm grade III and IV
and to explore whether Botulinum neurotoxin type A treatment improves their quality of life. We used a WHOQOL-BREF
questionnaire, based on the existing WHO recommendation and its meaningful metric characteristics. The study in-
cluded 37 patients with either grade/type III or IV blepharospasm who were treated with Botulinum neurotoxin Type A.
Each patient completed the WHOQOL-BREF questionnaire by themselves just before the Botulinum Neurotoxin Type A
(BT-A) therapy application, when the cilinical symptoms of blepharospasm were most manifest and a month and a half
after, when the regression of symptoms appeare. Consequently, the application of BT-A resulted in improved changes in
terms of quality of life in 3 of the 4 measured fields (psychical and physical health as well as the environmental living
conditions).
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Introduction
WHO defines the quality of life as individuals’ percep-
tion of their position in life in the context of the culture
and value systems in which they live and in relation to
their goals, expectations, standards and concerns1. Sub-
jective evaluation of the quality of life of each individual
depends on interaction of its own psychological and envi-
ronmental conditions2,3. The presence of disease, as an
independent variable possibly relevant to the subjective
quality of life is not always necessary.
Studies that analyse the influence of different dis-
eases on quality of life do not necessarily correspond to
changes in quality of life which leads us to conclusion
that the disease by itself is not enough to change the per-
ception of life4,5.
Blepharospasm is a periodic, involuntary contraction
of orbicular muscle (m. orbicularis oculi) and can appear
alone or can be associated with dystonia6–9. The main
symptom is functional blindness and lower visual acuity
caused by continuous blinking which leads to reduction
of professional and everyday life activities.
Most patients have sensory symptoms at the onset,
such as dryness of the eyes, grittiness, irritation and
photophobia, continuous blinking aggravated in stress
and tiredness. Blepharospasms prevent patients from
reading, they limit the movement of patients so they be-
come dependent on other people, they are unable to
drive, which leads to social introversion and discomfort
while communicating with people. If the symptoms are
prolonged, they can result in serious psychological dis-
turbances10,11.
Blepharospasm is the first focal dystonia treated with
type A botulinum neurotoxin (BT-A)9, with a successful
treatment rate of 69–100% (double blind studies)12–15.
Application of Botulinum neurotoxin Type A leads to
symptom regression and »returns patients to normal
life«. BT-A is a unique example of the powerful exchange
in modern medicine, where a powerful poison becomes a
strong medicine with impressive therapeutic indications.
In the light of such objective Botulinum efficiency, we
wanted to analyse whether there are changes in the sub-
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jective perception of everyday quality of life in our patients,
and if there are improvements in their daily activities.
The recent publication has confirmed the improve-
ment in the quality of life of such patients11,16–18. How-
ever, self-estimation scales used in such studies, were
constructed strictly for that particular study. With this
study we wanted see the change in quality of life mea-
sured with the »Whoqol-bref« questionnaire following
the World Health Organisations (WHO) recommenda-
tion. This was due to its good metric characteristics, it’s
relatively easy to use nature and it’s applicable in differ-
ent areas of mental and somatic health, which enables
the comparison of definite results19–22.
The aim of this study was to analyse the quality of life
of patients with blepharospasm grade III and IV, that had
been treated with Botulinum neurotoxin type A (BT-A).
Whoqol-bref
Whoqol-bref is a shorter version of the Whoqol-100
scale the aims to measure a persons »quality of life« per-
ception. In turn, it indicates the same metric characteris-
tics as the original version of the scale, while the grading
system is comparable with a bigger scale. The scale con-
sists of 24 items and the patients answers use the 5
–point Likert scale. The scale measures 4 domains of
quality of life: physical activities of daily living: depend-
ence on medicinal substances and medicinal aids, energy
and fatigue, mobility, pain and discomfort, sleep and rest,
work capacity; psychological – bodily image and appear-
ance: negative feelings, positive feelings, self-esteem, spi-
rituality/religion/personal beliefs, thinking, learning,
memory, and concentration; social relationships – per-
sonal relationships: social support, sexual activity; and
environment – financial resource: freedom, physical sa-
fety and security, accessibility and quality of health care,
home environment, opportunities for acquiring new in-
formation and skills, participation in and opportunities
for recreation, physical environment (noise/traffic/clima-
te/transport); and 2 items regarding to general assess-
ment of satisfaction with life and satisfaction with health.
The score of each domain is defined by the sum of in-
dividual item scores on a subscale transformed into a
scale from 0 to 100, according to questionnaire instruc-
tions19–22.
Patients and Methods
The study included 37 patients with blepharospasm
grade III or IV who underwent treatment with Botuli-
num neurotoxin type A (BT-A). To weaken the orbital/
preseptal part of the orbicularis oculi, injections were
placed in the upper eyelid above the eyebrow, medially
and laterally, and in the lower eyelid laterally only. The
dose was 2.5–5.0 U in each site around each eye.
The exclusion criteria were psychiatric diagnoses and
intake of drugs that could have a sedative effect such as
sedatives, antipsychotic or antidepressant medicine whose
effect could interfere with study analyses.
The study was authorised by the Ethics/Ethical board
of Medical University in Zagreb. All patients filled in in-
formative question form. The study was conducted during
2004 at The Eye Clinic, Clinical Hospital Centre Zagreb.
Patients filled the WHOQOL-BREF questionnaire two (2)
times. The first time was on the day of the administration
of Botulinum Neurotoxin (i.e. when, according to the
opinion of ophthalmologists, the symptoms were most
prominent), and a month and a half after the administra-
tion of BT-A, when its efficiency was most evident.
Statistics
Kolmogorov-Smirnov Z-test was used to test the nor-
mality of distribution of the sample. The comparison of
the results was carried out by means of the Pairs T-test.
Non-parametric Wilcoxon Signed Ranks Test was used
for arithmetic mean difference analyses in variables which
were not distributed according to normal distribution.
Data were analyzed using the Windows based Statistica
7.1 software application for Windows.
Results
Socio-demographic data
The study included 37 patients: 10 men and 27 wo-
men, of an average age of 65±9.53 years (TR 47–84
years). Marriage status distribution was as follows: 23
patients (62%) were married; 11 widows, 1 divorced, 1
single. The educational profile was as follows: 7 patients
without elementary school education (18.9%), 6 with
only elementary school education (16.2%), 15 patients
with finished high school (40.5%), and 9 patients with
university education (24.3%).
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TABLE 1
THE AVERAGE RESULTS MEASURED WITH WHOQOL-BREF QUESTIONNAIRE IN PATIENTS BEFORE AND AFTER
ADMINISTRATION OF BT-A
Whoqol-bref / Domain
Baseline After 6 weeks
t-test p
X SD X SD
Physical health 12.1 2.87 13.8 3.01 –5.070 0.000
Psychological health 13.4 2.53 14.5 2.27 –4.564 0.000
Social relationship 13.2 3.36 13.4 3.27 –0.772 0.445
Environment 13.1 2.48 14.0 2.19 –3.269 0.002
The analysis (Table 1) shows that in 3 out of 4 mea-
sured domains there was statistical significance in the
assessment of quality of life. The participants are statis-
tically more satisfied with their physical health (p=
0.000), psychological health (p=0.000) and environment
(p=0.002). They are generally statistically more satisfied
with their life (p=0.029) and their health (p=0.024) (see
Table 2 below).
The most pronounced changes identified within the
Whoqol-bref questionnaire, where the items (refer to Ta-
ble 3 below) that indicated that the participants enjoyed
life more (p=0.002), felt physically safer in everyday life
(p=0.002), had enough energy in/for everyday life (p=
0.001) and performed everyday activities (p=0.005).
Discussion
Our study confirmed that the therapeutic application
of BT-A resulted in positive changes in the quality of life
in 3 out of 4 measured fields. Patients suffering from
blepharospasm were more satisfied with their psychical
and physical health as well as the environmental living
conditions.
Analyses of subjective satisfaction of patients with
their life and health were better after the therapy. As far
as psychological improvement in the quality of life is con-
cerned, the patients enjoy life more because they are able
to perform activities that have been unavailable to them
because of the problems they were having, such as knit-
ting, crocheting, making tapestries, reading…; their con-
centration has improved so they can focus better on their
working tasks, they are generally more satisfied with
themselves and they are less prone to negative emotions
such as bad mood, desperation, anxiety, depression…
In relation to the physical domain, they are more sat-
isfied with the medical treatment, since because of ble-
pharospasm they use different medications such as vita-
min supplements, certain herbal preparations, various
techniques for stopping blepharospasms such as yawn-
ing, pinching, pricking… with the aim of alleviating their
difficulties. By treating blepharospasm they have less
need for these medication methods, or the need disap-
pears completely. They have more energy in their every-
day life, since blepharospasms burdens the patients phy-
sically and psychologically and deprives them of the
energy for everyday activities23. They are more satisfied
with their sleep and their abilities for doing everyday ac-
tivities, which is logical since when the illness was at its
worst they were unable to drive a car (i.e. they were de-
pendent on others), or do household chores such as
ironing, cooking lunch… – they were functionally blind.
In relation to their environment, the patients feel
safer in their everyday life – by treating blepharospasm,
the patients’ physical security is increased, because the
possibility of personal injury is reduced (i.e. note, for
some patients – even crossing a pedestrian crossing was a
significant problem). They in fact, have increased their
possibilities for additional recreational activities.
Changes are also evident when it comes to particles
connected to the healthy environment, as well as the sat-
isfaction with living conditions. The administration of
botox is not in direct link with objective environmental
circumstances. However, while dealing with the subjec-
tive estimate of the quality of life, we may conclude that
they are more satisfied with life and health in general
and indirectly with their environment. As we stated in
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TABLE 2
THE AVERAGE RESULTS MEASURED WITH WHOQOL-BREF QUESTIONNAIRE IN PATIENTS BEFORE AND AFTER
ADMINISTRATION OF BT-A
Specific items
Baseline After 6 weeks
t-test p
X SD X SD
Life assessment 3.14 0.798 3.39 0.801 –2.311 0.029
Health assessment 2.67 1.179 3.11 0.965 –2.405 0.024
TABLE 3
STATISTICALLY SIGNIFICANT CHANGES IN SPECIFIC ITEMS




Perception of need of medical treatment
in everyday life –2.326 0.020
Perception of enjoying in life –3.074 0.002
Perception of ability concentrate –2.443 0.015
Physically safe in everyday life –3.117 0.002
Perception on healthy environment –2.140 0.032
Perception of energy for everyday life –3.378 0.001
Opportunity for recreation –2.368 0.018
Satisfaction with sleep –2.780 0.005
Satisfaction of ability to perform everyday
activities –2.057 0.040
Satisfaction on working abilities –2.100 0.033
Feeling of happiness with ourselves –2.309 0.021
Satisfaction of the friend’s support –2.080 0.038
Feeling of negative emotions such as bad
mood, desperation, anxiety, depression –2.200 0.028
Satisfaction with the conditions of living area –2.496 0.013
the introduction, blepharospasm can lead to serious psy-
chiatric disorders10. Thus it is not surprising that they
perceive changes in some objective and unchangeable cir-
cumstances, brought on by the absence of bad moods and
the increase in general well-being, which leads to satis-
faction with things not in direct connection. This only
justifies the administration of botox in the treatment
even more.
Changes have not been evident in the domain of social
relationships. We have not expected changes in this do-
main since we were dealing with a relatively short time
period. People of this age have made permanent friend-
ships that do not depend on current factors.
The effect of BT-A is visible already after 3–4 days,
and remission is achieved in 94% of patients. That means,
after its application, patients become quickly independ-
ent and functional and are not patients anymore.
However, the efficiency of therapy is not permanent,
and the symptoms can appear again after a period of 3–6
months. That can lead to a conclusion that the BT-A
treatment for blepharospasm is temporary and not a per-
manent solution. In turn, these patients can experience a
continuous bipolar curve effect: where they feel well or
worse, and the symptoms are more or less manifest. In-
cluding the simple fact and possibility that patients build
BT-A resistance, the imperative in future would be to
elaborate the blapharospasm etiology which would result
in more effective treatment in the context of remission.
Additionally, the following facts need to be highligh-
ted, while communicating with these patients, most of
them expressed scepticism towards the first suggested of
the botox application and after the first application. Only
once they have recieved the BT-A therapy and realise the
advantages of the BT-A application, they do not become
out of patience waiting for the next treatment (i.e..they
become less tolerant to disturbances.) Here we did not
accomodate or tolerate patients wishes to apply therapy
earlier than recommended, as the guidelines for blepha-
rospasm control are to administer low dosages in a lon-
ger timeframe as possible (i.e. intervals between each
treatment) aiming to prevent resistency.
The limitations of the study
These results must be taken with reserve because a
smaller sample of patients was included. The influence of
sex, age, educational level and marriage status were not
analysed as individual variables that can influence the
satisfaction estimation.
Since we included the data in the period of 6 weeks,
the improvement of the quality of life was not controlled
after 6 weeks, i.e. after the weakening of the effect of
BT-A.
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KVALITETA @IVOTA KOD OSOBA OBOLJELIH OD BLEFAROSPAZMA
S A @ E T A K
Ovim istra`ivanjem `eljeli smo prou~iti kvalitetu `ivota kod oboljelih od blefarospazma III i IV stupnja i istra`iti da
li tretman Botulinum neurotoxinom tipa A dovodi do pobolj{anja u kvaliteti `ivota. U istra`ivanju smo se koristili
WHOQOL –BREF upitnikom koji WHO preporu~ava za istra`ivanja jer ima dobre metrijske karakteristike. Istra`i-
vanjem je bilo obuhva}eno 37 pacijenata sa blefarospazmom III i IV stupnja koji su bili lije~eni botulinum neurotoksi-
nom tipa A. Ispitanici su popunjavali WHOQOL-BREF upitnik neposredno prije aplikacije injekcija Botulinum neu-
rotoksina tipa A, kada im je klini~ka slika bila najizra`enija, te mjesec i pol nakon aplikacije lijeka kada je do{lo do
regresije simptoma bolesti. Primjenom aplikacija BT-A je do{lo do promjene u kvaliteti `ivota u 3 od ~etiri mjerena
podru~ja (psihi~ko i fizi~ko zdravlje te zadovoljstvo okolinskim uvjetima).
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